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total virus particle determination
Petra Kramberger1,2*, Mateja Ciringer2, Aleš Štrancar1,2 and Matjaž Peterka1,2Abstract
The NanoSight LM10 with Nanoparticle tracking analysis (NTA) software was evaluated for the quantification of
latex particles, adenovirus 5, and influenza virus. The inter-day variability was determined by measuring the same
sample over several consecutive days and the method’s accuracy was demonstrated by using known
concentrations of the subject particles. NTA analysis was also used to quantify chromatographic fractions of
adenovirus and influenza virus after purification on a CIM monolithic column. NTA results were compared and
evaluated against hemagglutination (HA) and end point dilution assay, determining total and infection virus particle
number, respectively. The results demonstrated that nanoparticle tracking analysis is a method for fast estimation of
virus concentration in different samples. In addition, it can provide a better insight into the sample status, regarding
the level of virus aggregation.
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Vaccines play an important role in the prevention and
treatment of disease. Although vaccines have been used
for decades, there has only recently been a concerted ef-
fort to optimize their production and improve vaccine
safety and efficacy [1-3]. Apart from vaccines, where
virus particles work as a preventive tool, they also have
the potential to work as therapeutics: viral vectors for
gene therapy [4-7] and bacteriophages for the treatment
of bacterial infections [8-11].
The downstream processing (DSP) of vaccines repre-
sents a considerable production cost. During these puri-
fication steps, it is critical to monitor impurity removal
and virus recovery in order to stop production runs as
early as possible if a problem is detected. Since DSP
strongly depends on the consistency of the up-stream
process (USP), virus titre monitoring during USP is just
as critical and important as during DSP.
The infective viral titre is determined by using the tis-
sue culture infectious dose 50 (TCID50), plaque assay
and end point dilution assay. In contrast to infectivity
assays, which are laborious and time-consuming, total* Correspondence: petra.kramberger@monoliths.com
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distribution, and reproduction in any mediumvirus particles quantification methods are in general
relatively quick, but have some other drawbacks.
Spectrophotometric-based measurement of virus con-
centration (absorbance ratio 260/280 nm) can be applied
only for highly purified virus preparations; quantitative
real time polymerase chain reaction (qPCR) measures
gene copy rather than particles and thus excludes empty
capsids from the analysis [12]; transmission electron mi-
croscopy (TEM) has high variability in determining total
virus counts and is quite time consuming and costly.
None of the above mentioned (infectivity and non-
infectivity) methods enables the assessment of virus
aggregation and complex formation. In a non-natural
environment, such as low pH for influenza virus [13],
viruses tend to aggregate with other virus particles or
form complexes with impurities [14]. During DSP, these
need to be removed as soon as possible to prevent or
minimize further aggregation. At the later stages of DSP,
aggregates occur due to high virus concentration [15,16].
The level of virus aggregation should be monitored
throughout the downstream processing because this
phenomenon can influence the behavior of some viruses
like influenza A virus where aggregation inhibits virus
hemagglutination activity and infectivity [17]. This con-
sequently impacts the results obtained with virus quanti-
fication methods used at the end of DSP when vaccinentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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infectivity assays.
Factors that contribute to particle aggregation and
methods to prevent its occurrence during virus purifica-
tion and formulation were highlighted by Wright et al.
[14]. Using recombinant virus vector AAV2, they
demonstrated that aggregation cannot be prevented by
different sugars or surfactants, but can be using various
salts at concentrations corresponding to a solution ionic
strengths of more than 200 mM [14].
For determination of virus particle size and distribu-
tion (aggregation), field flow fractionation connected
with multiangle light scattering (FFF-MALS) and size
exclusion chromatography coupled with MALS (SEC-
MALS) were evaluated by Wei et al. [12]. These meth-
ods were than compared with several other methods:
transmission electron microscopy (TEM), atomic force
microscopy (AFM), quantitative reverse transcription
polymerase chain reaction (RT Q-PCR), median tissue
culture dose (TCID50), and the fluorescent focus assay
(FFA). All of the methods evaluated have their own
advantages and limitations and are complementary to
each other. The selection of one specific method
depends on the issue being examined [12].
For some applications, the ratio between total virus
and infective virus particles is of great importance (e.g.
gene therapy vectors), while for the others (e.g. inacti-
vated viral vaccines) the total virus particle count is suf-
ficient. To speed up downstream process development
while simultaneously reducing costs, a total virus par-
ticle quantification method should be employed that is
quick, reliable, and robust to enable the quantification of
virus throughout the purification process.
Nanoparticle tracking analysis (NTA) is a system for
sizing particles from about 30 to 1000 nm and ability to
determine the concentration of particles in the solution
within the concentration range from 10E+7 to 10E+9
particles/ ml depending on sample type. The technique
combines laser light scattering microscopy with a
charge-coupled device (CCD) camera operating at 30
frames per second, which enables the visualization and
recording of nanoparticles in solution. The NTA soft-
ware is then able to identify and track individual nano-
particles moving under Brownian motion and the
results allow particle number concentration to be recov-
ered. NTA was already evaluated for the measurement
of nanoparticles [18], drug delivery nanoparticles and
protein aggregates [19] and recently, ASTM has pub-
lished a guideline on the use of NTA for Measurement
of Particle Size Distribution of Nanomaterials in Sus-
pension [20].
Our goal was to evaluate the potential of the Nano-
particle tracking analysis for virus particle quantification
and assessment of the level of virus particles aggregation.A direct comparison with hemagglutination assay and in-
direct comparison with End-point Dilution Assay was
made in order to reveal the advantages and drawbacks of
a technique.
Materials and methods
Latex particles, viruses and virus sample preparation
Latex particles (120 nm in diameter; standard deviation:
21 nm) were purchased from Christine Grőpl (Tulln,
Austria). Approximate particle concentration (1.05E+12
LP/ml of latex particles) was provided by manufacturer.
Adenoviruses are medium-sized (90–100 nm), non-
enveloped, icosahedral viruses composed of a nucleo-
capsid and a double-stranded linear DNA genome.
Adenovirus 5 (Ad5) was propagated in HEK293 cells
and released from the cells by three cycles of freezing in
a dry ice/ethanol bath and thawing in a 37°C water bath.
After centrifugation at 6.500 x g for 10 min, the super-
natant was treated with benzonase (Merck, Darmstadt,
Germany) for 1h at 37°C and filtered using a 0.22 μm
PES filter (TPP, Trasadingen, Switzerland). The benzo-
nase treated and filtered virus harvest was purified on a
strong anion exchanger, CIM QA monolithic column, as
previously reported by Lah et al. [21].
Influenza virus (H1N1) was propagated in Vero cells,
using serum free medium. The virus was harvested,
benzonase treated, and concentrated by tangential flow
filtration (PeliconW XL Device, 300.000 NMWC, Milli-
pore). The concentrated virus harvest was then filtered
using a 0.45 μm ChromafilW cellulose acetate (CA)
membrane (Macherey-Nagel, Düren, Germany) and
diluted 1:1 (v/v) with 50 mM HEPES pH 7.5 (equili-
bration buffer used for chromatography). The virus
was purified on a strong cation exchanger, CIM SO3
monolithic column, using the method developed and
described by Peterka et al. [22].
Nanoparticle tracking analysis (NTA)
NTA measurements were performed using a NanoSight
LM10 instrument (NanoSight, Amesbury, UK), consist-
ing of a conventional optical microscope, Marlin charged
coupled device (CCD) camera, and a LM10 unit (sample
unit) with a laser light source. LM10 is the first gener-
ation instrument from the NanoSight Company, which
in the mean time has developed devices with additional
features and upgraded software.
Following the manufacturer’s instructions, we serially
diluted all samples with sterile water or DPBS to reach a
particle concentration suitable for analysis with NTA
(1.0E+8 to 2.5E+9 particles/ml). We prepared at least
two different sample dilutions for each sample and ana-
lyzed each one twice. The samples were injected into the
LM unit (approximately 300 μl) with a 1 ml sterile syr-
inge. The capturing settings (shutter and gain) and
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protocol suggested in the Technical note ”How to
make Concentration Measurements using NanoSight
Equipment” (Technical Note, NanoSight, last updated
17/06/09) and then optimized for a specific virus or
the latex particles. The NanoSight LM10 recorded
60 second sample videos which were than analyzed
with the Nanoparticle Tracking Analysis (NTA) 2.0 Ana-
lytical software release version build 0125.Hemagglutination assay
To estimate the total number of influenza virus particles,
a standard hemagglutination assay (HA) using standar-
dized concentration of avian red blood cells (0.5% RBC)
as previously described by John Hierholzer et al. [23,24]
was used.
A serial twofold dilution of the virus was prepared in
U-bottomed 96 well microtiter plates containing 50 μl
DPBS. Into each well, a 50 μl of 0.5% solution of chicken
red blood cells was added and the plate was incubated
for 60 minutes at room temperature. HA titres (HA/ml)
were read as the reciprocal dilution of the last well
showing hemagglutination.End point dilution assay
The infective virus titre of Ad 5 was determined by End-
point Dilution (EPD) Assay. The assay is based on ob-
serving the cytopathic effect (CPE) of serially diluted
adenovirus samples in HEK293 cells cultured in 96-well
plates. CPE was examined 7–10 days after infection and
the virus titre was calculated based on the dilution
factors.Chromatography
A CIMW monolithic column (BIA Separations, Ljubljana,
Slovenia) with a dimension of 12 mm x 3 mm i.d. and
bed volume of 0.34 ml were used for purification of
adenovirus and influenza virus. The column was
attached to a Knauer (Berlin, Germany) gradient HPLC
system, consisting of two K-500 pumps, a UV–VIS de-
tector K-2500 set to 280 nm, and a data acquisition
and control station with a PEEK capillary tube (i.d.
0.75 mm). A conductivity meter (GE Healthcare, Upp-
sala, Sweden) was added to the system. The adenovirus
was purified on a strong anion exchanger (CIM QA
monolithic column) using a 50 mM Tris containing 2
mM MgCl2 and 0.4 M NaCl, pH 8 equilibration buffer.
The influenza virus was purified on a strong cation ex-
changer (CIM SO3 monolithic column) using a 50
mM HEPES equilibration buffer, pH 7.5. Both viruses
were eluted from the column using high NaCl concen-
tration in equilibration buffer.Results and discussion
Quantitation of latex particles
The NTA method was first characterized by quantifying
latex particles with a diameter of 120 nm at a concentra-
tion of 1.05E+12 LP/ml. These latex particles were used
as a model nanoparticle since their size is similar to that
of the two tested viruses (adenovirus and influenza). We
assumed that the NTA method settings determined for
the latex particles would be applicable for the viruses as
well.
The settings selected for the video capturing of the
latex particles were set according to the manufacturer’s
instructions. The videos were analyzed under different
conditions by changing brightness, blur, gain, and detec-
tion threshold. By comparing the concentration of latex
particles in differently diluted samples, analyzed with dif-
ferent settings, we were able to determine which settings
have a smaller or greater effect on the result (data not
shown). Similar to the previously published findings by
Filipe et al. [19], it was observed that the settings that
have a major influence on the results are: shutter, gain,
blur and detection threshold. Therefore, these settings
were kept the same for the analysis of several dilutions
of the same latex particle sample.
The videos were analyzed using the optimal settings
determined for latex particle quantification with NTA:
brightness −15, gain 2, blur 5x5 and detection threshold
30 (Table 1). Results obtained were subjected to the
screening: The number of completed tracks had to be at
least 200 or above and the average number of particles/
frame had to be between 20 and 60. We also found that
the ratio between the theoretical factor and a measured
one which needed to be between 0.8 and 1.2 (Table 1,
last column) was also important.
This means that we allowed up to a 20% deviation in
the titre determined between the two consecutive dilu-
tions of the same sample to recognize the measurement
as a “relevant” one. The limit of 20% was set on the basis
of recommendations from the U.S. Department of
Health and Human Services, Food and Drug Adminis-
tration, and others set in the guidance for Bioanalytical
Method Validation [25]. By introducing this last criter-
ion, an additional (back-up) system for the recognition
of relevant measurements was established. Linearity-of-
dilution is shown in Figure 1.
We also monitored the operator-to-operator variability
(data not shown) and it was determined that it is within
the acceptable range of 15-20% for the accuracy of bioa-
nalytical methods [25].
Quantitation of adenoviruses
Since the particle size of an adenovirus is 100 nm in
diameter which is similar to the 120 nm latex particles,
the parameters used for the analysis were similar to






















300 1 91* 2896 115 1,52E+09
2 79* 2407 119 1,27E+09 1,4E+09 4,2E+11
500 1 120* 4179 100 1,93E+09 0,7 1,7 2,3
2 115* 3999 103 1,86E+09 1,9E+09 9,5E+11
900 1 87* 2621 125 1,40E+09 1,4 1,8 1,3
2 80* 2253 133 1,29E+09 1,3E+09 1,2E+12
1000 1 64* 2004 125 1,03E+09
2 35 755 143 5,69E+08
3 23 575 131 3,78E+08 4,7E+08 4,7E+11
1500 1 61* 2005 106 9,92E+08 0,6 1,5 2,6
2 52 1688 110 8,35E+08 8,4E+08 1,3E+12**
2000 1 29 748 130 4,71E+08 1,7 1,3 0,8
2 33 1004 109 5,38E+08 5,0E+08 1,0E+12**
3000 1 13* 343 149 2,16E+08 1,3 1,5 1,2
2 24 640 146 3,90E+08
3 24 681 127 3,94E+08 3,9E+08 1,2E+12**
1,15E+12 Final concentration (LP/ml)
* Measurements where the “particle/frame” was higher than 60 or lower than 20 (consequently these measurements were eliminated from final calculation).
**Concentration values with TF/MF factor between 0.8 and 1.2 (these values were used to calculate the original concentration of latex particles).
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shutter speed of between 1340 and 1500 and the gain
was set to the maximal value. The videos were processed
with the brightness set to −15, gain 2, blur 3x3 and de-
tection threshold 30.
To establish the inter-day variability/repeatability of
the NTA method, the same adenovirus sample was
assayed for 4 consecutive days. Between the measure-























Figure 1 Latex particle analysis: linearity of dilution. Grey columns rep
represent the measured titre. Only the last three dilutions measured fulfille
60 and the TF/MF factor between 0.8 and 1.2) and were used to calculateday the adenovirus sample was thawed, two dilutions
were prepared (with DPBS), and each dilution was ana-
lyzed twice. The inter-day variability of the method was
determined to be 14% (Table 2). We are presuming that
the freeze-thawing of the sample did not have any effect
(aggregation or disruption of virus particles) on the
adenovirus total particles titre. This is reasonable since
the average particle size during the course of experiment
was not changed.1000 1500 2000 3000
n of latex particles
Theoretical titre (LP/ml)
Measured titre (LP/ml)
resent the theoretical titre of latex particles, while the black columns
d both criteria (average particle number in the range between 20 and
the original concentration of latex particles.
Table 2 Inter-day variability of the NTA method







MF TF TF/MF Conc.
(VP/ml)
Day 1 20 6,90E+08
20 4,27E+08 5,59E+08 1,12E+10
30 4,63E+08 1,3 1,5 1,1 1,2E+10
30 3,73E+08 4,18E+08 1,25E+10
Day 2 20 6,08E+08
20 8,12E+08 7,10E+08 1,42E+10
30 4,89E+08 1,4 1,5 1,1 1,5E+10
30 5,49E+08 5,19E+08 1,56E+10
Day 3 20 6,28E+08
20 6,75E+08 6,52E+08 1,30E+10
30 5,50E+08 1,3 1,5 1,2 1,4E+10
30 4,60E+08 5,05E+08 1,52E+10
Day 4 20 5,73E+08
20 5,35E+08 5,54E+08 1,11E+10
30 3,79E+08 1,5 1,5 1,0 1,1E+10




Inter-day variability of the NTA method determined by measuring the same sample (Ad5 virus) for 4 consecutive days. MF- the ratio between concentrations of
two sample dilutions determined with NTA; TF-the ratio between two dilutions of the same sample analyzed.
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recovery method. The original latex particle (LP) solu-
tion, containing particles with a diameter of 120 nm at a
concentration of 1.05E+12 LP/ml, was diluted 10-fold
with DPBS. The resulting theoretical concentration was
1.05E+11 LP/ml which was then used as a spike.
Since 5 μl of the 10-fold diluted latex solution was
added to the adenovirus sample as a spike, the total
particle titre added corresponds to 5.25E+8 LP/5 μl.
In Table 3, this is listed as the “theoretical latex
spike”. In parallel, the actual titre of the ten-foldTable 3 Accuracy of NTA determined by spike-and-recovery m
Dilution of Ad sample for NTA analysis
Theoretical latex spike (LP/5μl)
Measured latex spike (LP/5μl)
Concentration of non-spiked Ad sample (VP/ml)
Concentration of spiked Ad sample (particles/ml)
Δ (spiked Ad sample-non-spiked Ad sample)
Recovery of latex spike sample according to measured spike (%)
Recovery of latex spike sample according to theoretical spike (%)diluted latex solution was measured: 5 μl of the spik-
ing solution was added to the DPBS buffer and ana-
lyzed with NTA (“measured latex spike”, Figure 2).
The theoretical and measured latex spike concentra-
tions was very similar (Table 3) and were used to de-
termine the recovery of the latex spike added to the
adenovirus samples.
Since the adenovirus particle size is relatively close to
the latex particles, we used the same shutter speed and














Figure 2 Particle size distribution of latex spiking solution. Particle size distribution of ten-fold (1:9, v/v) diluted original latex solution (spiking
solution) added to DPBS (measured latex spiking solution).
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concentration, were chosen for the analysis. The first
adenovirus sample was treated with benzonase and fil-
tered through a 0.22 μm filter and the second was puri-
fied using an anion exchange chromatography resin,
CIM QA monolithic column. Both samples were ana-
lyzed with and without the addition of the spike and the
concentrations obtained were compared and spike re-
covery was calculated (Table 3). Spike recovery was very
similar for the non-purified and CIM purified adeno-
virus, although the virus concentrations in these two
samples differed greatly. Since the theoretical (calcu-
lated) concentration of the latex spike sample differed
from the measured one by only 3%, the recovery of
the latex spike was also very close. According to spike










Figure 3 Shematical chromatograph of virus purification. Flow-throug
washed from the column), elution 1 (the main virus fraction), elution 2 (elu
elution in this case is achieved by increasing salt concentration (indicated wconcentration of particles (latex and/or adenovirus) in
the sample for around 15%. The accuracy of the mea-
surements is still within the 20% as accepted by Bioanaly-
tical Method Validation [25] however the measurements
tend to show a small systematic shift for witch the reason
is still unclear.
To minimize the inter-day and operator to operator
variability of NTA, a set of chromatographic fractions
(schematically shown on Figure 3) obtained during
adenovirus purification on a CIM QA monolithic col-
umn were analyzed within the same day by the same op-
erator. In addition, the fractions were also analyzed by
End point dilution (EPD) assay.
Since EPD enables the quantification of the infective
virus particles and NTA the quantification of total virus
particles, the two methods cannot be directly compared.min)
Wash Elution 1 Elution 2
h fraction (non- bound compounds), wash (weakly bound compounds
tion of strongly bound impurities-usually host cell DNA). Selective
ith the grey line).
Table 4 Comparison of EPD and NTA method
EPD NTA
Fraction Volume (ml) PFU/ml PFU total PFU rec.(%) VP/ml VP total VP rec. (%)
Load 36 1,00E+08 3,60E+09 1,03E+10 3,71E+11
Flow through 1 10,0 6,31E+02 6,31E+03 0,0 1,12E+08 1,12E+09 0,3
Flow through 2 26,0 1,00E+03 2,60E+04 0,0 1,59E+08 4,13E+09 1,1
Wash 23,0 NA 3,03E+08 6,97E+09 2
Elution 1 1,2 2,00E+09 2,40E+09 66,7 1,79E+11 2,14E+11 57,8
Elution 2 3,0 6,31E+06 1,89E+07 0,5 1,14E+09 3,41E+09 1
SUM 67,2 62,0
Analysis of adenovirus purification on CIM QA monolithic column by NTA and EPD assay.
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(Table 4), there was a good correlation between both
methods.
The method used to purify the adenovirus was not
optimized and only performed on a laboratory scale for
the purpose of evaluating the NTA method. Therefore,
the virus recovery as well as the ratio between infective
and non-infective particles is not optimal.
Quantitation of influenza virus
In order to compare the NTA method with another fre-
quently used method for total virus quantification, two
sets of samples (chromatographic fractions) obtained
during influenza virus purification on a CIM monolithic
column were analyzed by the NTA method and
hemagglutination assay.
The hemagglutination assay is based on the binding
(agglutination) of red blood cells (RBCs) which occurs
after a certain concentration of viruses have attached to
the RBCs surface. The ability of viruses to agglutinate
RBCs is rarely linked to their infectivity [26] therefore
the method can be applied to quantify the total number
of virus particles. By serially diluting a virus suspension
and adding a standard amount of RBCs, an estimation ofTable 5 Comparison of HA and NTA method
HA
V (ml) HA (HA/ml) Total HA (HA) R
Load 1,5 128 192,0
1 FT 2,9 <1
1 E1 1 128 128,0
1 E2 1,15 4 4,6
Total recovery (%)
2 FT 2,4 <1
2 E1 0,9 128 115,2
2 E2 1,1 4 4,4
Total recovery (%)
Analysis of chromatographic samples collected during influenza virus purification o
through fraction) and E (elution fractions).the virus particles presence (in HA units/ml) was made
and compared with the virus titre determined by the
NTA method (Table 5).
In the majority of the samples tested, the virus pres-
ence (compared on the level of the virus recovery)
obtained by the HA and NTA method were comparable.
In 6 out of 7 samples analyzed, the NTA method deter-
mined a slightly higher virus content and consequently
virus recovery compared to the HA assay. This was to
some extent expected since the NTA sample analysis
showed a broader size distribution of peaks than
expected based upon the size of the influenza virus
(Figure 4). This indicates that the samples analyzed
contained to some extent virus particle aggregates.
This is especially evident for the influenza virus sample
before purification on CIM SO3 column (Figure 4A).
The main difference between the results obtained by
both methods is the virus presence determined in the
flow-through fraction (in both chromatographic purifi-
cations of influenza virus). While no virus (or less than
1 HA unit/ml) was detected with the HA assay, the NTA
measurement showed the presence of the virus reflect-
ing a virus recovery of 13% and 16%, respectively. This
discrepancy between the measurements of the virusNTA
ecovery (%) NTA (VP/ml) Total titer (VP) Recovery (%)
5,7E+09 8,6E+09
4,1E+08 1,2E+09 13,8
66,7 5,8E+09 5,8E+09 68,0
2,4 1,5E+08 1,7E+08 2,0
69,1 83,0
6,0E+08 1,4E+09 16,7
60,0 7,2E+09 6,5E+09 75,4
2,3 3,7E+08 4,1E+08 4,7
62,3 96,8
n two different CIM SO3 monolithic columns by HA and NTA method; FT (flow-
Figure 4 Particle size distribution of influenza virus. Particle size distribution of influenza virus before (A) and after (B) purification on CIM
SO3 monolithic column; both samples diluted 1:20 (v/v) with DPBS.
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relatively big difference in total virus recovery deter-
mined by both methods.
There are two hypothesis why no virus could be
determined in the flow-through fraction by the HA
method, while this was not the case with the NTA
method. The first one is connected to virus aggrega-
tion in the flow-through fraction resulting in an under-
estimation of virus particles determined with the HA
assay. This phenomenon was previously described by
Kalbfuss et al. [27]. But this theory could only be sup-
ported if the average size of the virus particles in the
flow-through fraction would indicate aggregation, which
was not the case. The second hypothesis is based on the
fact that in the flow-through fraction the virus particles
which the NTA method was able to detect lost theability to agglutinate erythrocytes and could therefore
not be detected by the HA assay. Since the ability of
viruses to agglutinate RBCs is rarely linked to the virus
infectivity [26], this hypothesis would be very hard to
prove even with an infectivity assay.
In any case, the NTA method proved to be suitable for
a quick estimation of total virus particles in chromato-
graphic samples of influenza virus and could be used as
a sole or a complementary method for virus recovery
estimations.
In general, the data obtained by the NTA should be
interpreted with care. It is very important that enough
particles are tracked and that the right settings are
chosen. After analysis only the “relevant” data should be
used for the calculation of the final particle concentra-
tion, following the criteria discussed earlier (the number
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frame and the ratio between the theoretical factor and a
measured one).
Conclusions
During downstream processing development, it is very
important to monitor virus recovery. To determine the
virus recovery, different virus samples (e.g. chromato-
graphic fractions) containing different virus titres have
to be analyzed and compared with the starting material.
Titres of different virus samples can only be compared if
they are analyzed under the same conditions. In the case
of NTA, this means the analysis is performed using the
same parameters. To determine this, the optimal settings
to enable virus quantification over a large span of virus
titters should be identified.
Since the virus material during DSP development con-
tains different concentration of viruses, linearity of the
method is a key feature. The optimal set of NTA para-
meters should therefore enable virus quantification over
a large span of virus titters. The method’s linearity can
be determined by assaying different dilutions of the virus
sample and calculating the ratio between the theoretical
linearity factor and a measured one (TF/MF ratio).
Inter-day variability of the method should also be
taken into account by comparing several samples on dif-
ferent days. In addition, the accuracy of the NTA
method, shown by spike and recovery method indicates
that the NTA method underestimates the titre of adeno-
virus for approximately 15%.
Comparison of NTA with HA assay showed that NTA
can successfully substitute the HA method when infect-
ivity of the virus is not an issue. In addition, it can pro-
vide a better insight into the sample status, regarding
the level of virus aggregation.
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